NYSEAMERICAN:PFNX - Pfenex Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$5.30 +0.04 (+0.76 %)
(As of 06/21/2018 04:00 PM ET)
Previous Close$5.26
Today's Range$5.01 - $5.35
52-Week Range$2.07 - $8.42
Volume331,600 shs
Average Volume162,515 shs
Market Capitalization$106.11 million
P/E RatioN/A
Dividend YieldN/A
Beta3.6
Pfenex logoPfenex Inc., a clinical-stage biotechnology company, develops biosimilar therapeutics in the United States. The company's lead product candidates include PF708, a therapeutic equivalent candidate to Forteo (teriparatide) for the treatment of osteoporosis; and novel anthrax vaccine candidates, such as Px563L and RPA563 that are in Phase I study. It develops PF529, a biosimilar candidate to Neulasta; PF530, a biosimilar candidate to Betaseron; and hematology/oncology products, including PF743 and PF745. The company has collaboration agreement with Jazz Pharmaceuticals Ireland Limited and Hospira, Inc., as well as a contract agreement with The National Institute of Allergy and Infectious Diseases. Pfenex Inc. is headquartered in San Diego, California.

Receive PFNX News and Ratings via Email

Sign-up to receive the latest news and ratings for PFNX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolNYSEAMERICAN:PFNX
CUSIPN/A
Phone+1-858-3524400

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-175.52%
Return on Equity-63.57%
Return on Assets-46.31%

Miscellaneous

EmployeesN/A
Outstanding Shares23,580,000

Pfenex (NYSEAMERICAN:PFNX) Frequently Asked Questions

What is Pfenex's stock symbol?

Pfenex trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "PFNX."

How were Pfenex's earnings last quarter?

Pfenex Inc (NYSEAMERICAN:PFNX) announced its earnings results on Thursday, May, 10th. The biotechnology company reported ($0.47) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.43) by $0.04. The biotechnology company had revenue of $3.75 million for the quarter, compared to analyst estimates of $5.52 million. Pfenex had a negative return on equity of 63.57% and a negative net margin of 175.52%. View Pfenex's Earnings History.

When is Pfenex's next earnings date?

Pfenex is scheduled to release their next quarterly earnings announcement on Tuesday, August, 7th 2018. View Earnings Estimates for Pfenex.

What price target have analysts set for PFNX?

3 brokerages have issued 1-year price objectives for Pfenex's stock. Their forecasts range from $8.00 to $8.00. On average, they anticipate Pfenex's share price to reach $8.00 in the next year. View Analyst Ratings for Pfenex.

Who are some of Pfenex's key competitors?

Who are Pfenex's key executives?

Pfenex's management team includes the folowing people:
  • Dr. Hubert C. Chen, Chief Medical & Scientific Officer (Age 49)
  • Mr. Evert B. Schimmelpennink, CEO, Pres, Sec. & Director (Age 46)
  • Ms. Susan A. Knudson, Chief Financial Officer (Age 54)
  • Ms. Patricia Lady C.M.A., C.P.A., M.B.A., CPA, MBA CMA, Chief Accounting Officer (Age 60)
  • Mr. Patrick K. Lucy, Chief Bus. Officer (Age 50)

Has Pfenex been receiving favorable news coverage?

News coverage about PFNX stock has been trending somewhat positive on Thursday, Accern Sentiment reports. Accern rates the sentiment of media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Pfenex earned a coverage optimism score of 0.16 on Accern's scale. They also assigned headlines about the biotechnology company an impact score of 46.73 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near future.

Who are Pfenex's major shareholders?

Pfenex's stock is owned by a variety of of retail and institutional investors. Top institutional investors include PRIMECAP MANAGEMENT COMPANY (10.54%), Blair William & Co. IL (5.81%), Dimensional Fund Advisors LP (1.91%), BlackRock Inc. (1.56%), C WorldWide Group Holding A S (0.85%) and Millennium Management LLC (0.45%). Company insiders that own Pfenex stock include Jason Grenfell-Gardner, Patricia Lady, Patrick K Lucy and Signet Healthcare Partners Acc. View Institutional Ownership Trends for Pfenex.

Which institutional investors are selling Pfenex stock?

PFNX stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, BlackRock Inc. and C WorldWide Group Holding A S. View Insider Buying and Selling for Pfenex.

Which institutional investors are buying Pfenex stock?

PFNX stock was acquired by a variety of institutional investors in the last quarter, including Blair William & Co. IL, Dimensional Fund Advisors LP and Commonwealth Equity Services LLC. View Insider Buying and Selling for Pfenex.

How do I buy shares of Pfenex?

Shares of PFNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Pfenex's stock price today?

One share of PFNX stock can currently be purchased for approximately $5.30.

How big of a company is Pfenex?

Pfenex has a market capitalization of $106.11 million.

How can I contact Pfenex?

Pfenex's mailing address is 10790 Roselle St, SAN DIEGO, CA 92121-1508, United States. The biotechnology company can be reached via phone at +1-858-3524400.


MarketBeat Community Rating for Pfenex (PFNX)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  139 (Vote Outperform)
Underperform Votes:  110 (Vote Underperform)
Total Votes:  249
MarketBeat's community ratings are surveys of what our community members think about Pfenex and other stocks. Vote "Outperform" if you believe PFNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PFNX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.